- ¥4bn
- ¥998m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.34 | ||
| Price to Tang. Book | 1.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,968.15 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -35.52% | ||
| Return on Equity | -28.76% | ||
| Operating Margin | -52334.88% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 121.39 | 91.96 | 80.91 | 65.97 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.
Directors
- Masatoshi Fujiwara EXO
- Masayuki Miyazaki EXO (66)
- Tomonari Adachi EXO
- Kazuaki Aoki EXO
- Katsunori Miyoshi EXO
- Yoshikazu Nakamura DRC (70)
- Emiko Nakamura DRC (39)
- Hirofumi Morikawa IND
- Toshiaki Nishihata IND (69)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 1st, 2003
- Public Since
- September 25th, 2014
- No. of Shareholders
- 16,128
- No. of Employees
- 24
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Tokyo Stock Exchange- Shares in Issue
- 44,590,128
- Address
- 6F, Shirokanedai Usui Bldg., MINATO-KU, 108-0071
- Web
- https://www.ribomic.com/
- Phone
- +81 334403303
- Auditors
- KPMG AZSA LLC
Upcoming Events for 4591
Similar to 4591
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics Co
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
Chiome Bioscience
Tokyo Stock Exchange
FAQ
What is the Ribomic share price?
As of Today at 22:56 UTC, shares in Ribomic are trading at ¥93. This share price information is delayed by 15 minutes.
How has the Ribomic share price performed this year?
Shares in Ribomic last closed at ¥93 and the price had moved by +13.41% over the past 365 days. In terms of relative price strength the Ribomic share price has outperformed the Nikkei 225 Index by +19.52% over the past year.
What are the analyst and broker recommendations for Ribomic?
There is no consensus recommendation for this security.
Find out moreWhat is the Ribomic dividend yield?
Ribomic does not currently pay a dividend.
Does Ribomic pay a dividend?
Ribomic does not currently pay a dividend.
When does Ribomic next pay dividends?
Ribomic does not currently pay a dividend.
How do I buy Ribomic shares?
To buy shares in Ribomic you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ribomic?
As of the previous close price of ¥93, shares in Ribomic had a market capitalisation of ¥4bn.
Where are Ribomic shares listed?
Here are the trading details for Ribomic:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4591
What kind of share is Ribomic?
Based on an overall assessment of its quality, value and momentum Ribomic is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ribomic share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Ribomic share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ribomic. Over the past six months, its share price has outperformed the Nikkei 225 Index by +34.07%.
As of the last closing price of ¥93, shares in Ribomic were trading +4.24% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ribomic PE Ratio?
The Ribomic PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥93.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ribomic?
Ribomic's management team is headed by:
- Masatoshi Fujiwara - EXO
- Masayuki Miyazaki - EXO
- Tomonari Adachi - EXO
- Kazuaki Aoki - EXO
- Katsunori Miyoshi - EXO
- Yoshikazu Nakamura - DRC
- Emiko Nakamura - DRC
- Hirofumi Morikawa - IND
- Toshiaki Nishihata - IND